Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Conditions
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Blastic Phase Chronic Myelogenous Leukemia
- Childhood Acute Lymphoblastic Leukemia in Remission
- Childhood Chronic Myelogenous Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Chronic Phase Chronic Myelogenous Leukemia
- Philadelphia Positive Adult Acute Lymphoblastic Leukemia
- Philadelphia Positive Childhood Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Relapsing Chronic Myelogenous Leukemia
- Untreated Adult Acute Lymphoblastic Leukemia
- Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
- DRUG: nilotinib
- DRUG: imatinib mesylate
- OTHER: pharmacological study
Sponsor
Fred Hutchinson Cancer Center
Collaborators